What after Baker Bros. Advisors Lp’s Insider Buy of Seattle Genetics, Inc. (SGEN) Stock?; Last Week Harvest Capital Credit (HCAP) Analysts

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Harvest Capital Credit Corporation (NASDAQ:HCAP) Ratings Coverage

Among 3 analysts covering Harvest Capital Credit Corp (NASDAQ:HCAP), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Harvest Capital Credit Corp had 8 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was downgraded by Janney Capital to “Hold” on Friday, February 9. The firm earned “Market Perform” rating on Thursday, August 11 by William Blair. The stock of Harvest Capital Credit Corporation (NASDAQ:HCAP) has “Hold” rating given on Wednesday, August 12 by Zacks. As per Sunday, October 22, the company rating was maintained by Keefe Bruyette & Woods. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Sunday, July 23. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, August 10. The firm earned “Hold” rating on Monday, April 2 by Keefe Bruyette & Woods. The firm earned “Hold” rating on Saturday, August 15 by Zacks. See Harvest Capital Credit Corporation (NASDAQ:HCAP) latest ratings:

02/04/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $11.5000 Maintain
09/02/2018 Broker: Janney Capital Rating: Hold Downgrade

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics has $77.0 highest and $4300 lowest target. $63.40’s average target is 16.48% above currents $54.43 stock price. Seattle Genetics had 67 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by RBC Capital Markets on Monday, November 13. The firm has “Hold” rating given on Monday, June 19 by Cowen & Co. The company was maintained on Monday, June 19 by H.C. Wainwright. On Friday, June 2 the stock rating was maintained by Oppenheimer with “Hold”. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Cowen & Co on Monday, June 26. SunTrust maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, October 27. SunTrust has “Hold” rating and $52.0 target. As per Wednesday, March 21, the company rating was maintained by Morgan Stanley. The company was downgraded on Friday, February 10 by Bank of America. The company was maintained on Monday, September 14 by RBC Capital Markets. The stock has “Hold” rating by Cowen & Co on Tuesday, June 6.

Since December 11, 2017, it had 1 buy, and 7 insider sales for $194.17 million activity. 10,457 shares were sold by DRACHMAN JONATHAN G, worth $552,452 on Monday, March 5. SIEGALL CLAY B sold $951,393 worth of stock or 18,832 shares. On Thursday, February 1 the insider BAKER BROS. ADVISORS LP bought $200.00 million. Shares for $290,604 were sold by HIMES VAUGHN B on Thursday, March 15.

The insider of Seattle Genetics Inc Wa, Baker Bros. Advisors Lp invested in 1.00 million shares of the corporation based on the average $51.3 for each one share. The insider shares are with market value of around $51.26 million U.S. Dollars. Due to the significance of this trade, it will not go ignored. Baker Bros. Advisors Lp owns 57.17% of the -company’s market cap with a total of 90.46 million shares. The purchase, dated May 02, 2018, is recorded on a Form 4 that was filed with the Washington-based Security and Exchange Commission and is also accessible here.

The stock increased 3.64% or $1.91 during the last trading session, reaching $54.43. About 1.71 million shares traded or 60.58% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 20.48% since May 3, 2017 and is downtrending. It has underperformed by 32.03% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $8.61 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Investors sentiment increased to 1.23 in Q4 2017. Its up 0.45, from 0.78 in 2017Q3. It increased, as 24 investors sold Seattle Genetics, Inc. shares while 67 reduced holdings. 44 funds opened positions while 68 raised stakes. 141.83 million shares or 1.14% more from 140.23 million shares in 2017Q3 were reported. Dimensional Fund Ltd Partnership has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Royal Comml Bank Of Canada holds 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 221,319 shares. Jfs Wealth stated it has 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Teacher Retirement Of Texas reported 27,125 shares or 0.01% of all its holdings. Nomura Asset Mgmt Ltd, Japan-based fund reported 12,600 shares. Stone Ridge Asset invested in 0.02% or 4,800 shares. Tudor Et Al holds 23,346 shares or 0.03% of its portfolio. Caisse De Depot Et Placement Du Quebec reported 0% stake. Van Eck Associate Corp holds 130,363 shares. Moreover, Whalerock Point Ltd Liability Company has 0.59% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). 6.43M were accumulated by Fmr Llc. Nordea, Sweden-based fund reported 2,762 shares. Guardian Trust owns 1.30M shares. First Lp has 0.08% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 633,794 shares. Barclays Pcl invested 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN).

Since December 14, 2017, it had 21 insider purchases, and 0 sales for $1.26 million activity. $77,778 worth of Harvest Capital Credit Corporation (NASDAQ:HCAP) shares were bought by JMP GROUP LLC.

Harvest Capital Credit Corporation (NASDAQ:HCAP) Institutional Positions Chart